Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takashi Shigematsu

Showing results (1-10 of 198) with videos related to

Pageof 20
Sort By:
Clinical and Experimental Nephrology|September 4, 2010
Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patientsTakashi Shigematsu,
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|February 9, 2008
Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysisTakashi Shigematsu,
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|May 5, 2010
One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysisTakashi Shigematsu,
Clinical Calcium|February 3, 2009
[Management of phosphate in chronic kidney disease--Clinical trials of lanthanum carbonate]Koichi Tatsuta, Takashi Shigematsu
Clinical Calcium|June 2, 2009
[Clinical aspect of recent progress in phosphate metabolism. Management of hyperphosphagtemia]Toshifumi Skaguchi, Takashi Shigematsu
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 21, 2011
Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study)Takashi Shigematsu, Shigeo Negi,
Clinical and Experimental Nephrology|August 29, 2012
Current therapeutic strategies for acute kidney injuryShigeo Negi, Takashi Shigematsu
Clinical Calcium|June 30, 2010
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease]Shigeo Negi, Takashi Shigematsu
Clinical Calcium|March 7, 2007
[Arteriosclerosis and vascular calcification in chronic kidney disease (CKD) patients]Yuri Masho, Takashi Shigematsu
Clinical Calcium|March 19, 2005
[PTH assay: whole PTH assay (new IRMA assay)]Yudo Tanno, Takashi Shigematsu
Pageof 20

Showing results (1-10 of 198) with videos related to

Sort By:
Pageof 20
Clinical and Experimental Nephrology|September 4, 2010
Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patientsTakashi Shigematsu,
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|February 9, 2008
Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysisTakashi Shigematsu,
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|May 5, 2010
One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysisTakashi Shigematsu,
Clinical Calcium|February 3, 2009
[Management of phosphate in chronic kidney disease--Clinical trials of lanthanum carbonate]Koichi Tatsuta, Takashi Shigematsu
Clinical Calcium|June 2, 2009
[Clinical aspect of recent progress in phosphate metabolism. Management of hyperphosphagtemia]Toshifumi Skaguchi, Takashi Shigematsu
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|July 21, 2011
Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study)Takashi Shigematsu, Shigeo Negi,
Clinical and Experimental Nephrology|August 29, 2012
Current therapeutic strategies for acute kidney injuryShigeo Negi, Takashi Shigematsu
Clinical Calcium|June 30, 2010
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease]Shigeo Negi, Takashi Shigematsu
Clinical Calcium|March 7, 2007
[Arteriosclerosis and vascular calcification in chronic kidney disease (CKD) patients]Yuri Masho, Takashi Shigematsu
Clinical Calcium|March 19, 2005
[PTH assay: whole PTH assay (new IRMA assay)]Yudo Tanno, Takashi Shigematsu
Pageof 20